QLT Aczone Clears FDA With Restricted Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling calls for testing for glucose 6-phosphate dehydrogenase deficiency before initiating treatment with Aczone (dapsone); patients with the enzyme deficiency should be monitored with regular blood counts. Patients are also advised to consider other acne therapies.